| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1043152044 |
| P356 | DOI | 10.1007/S40506-016-0085-5 |
| P932 | PMC publication ID | 5155020 |
| P698 | PubMed publication ID | 28035195 |
| P2093 | author name string | Hassan Zaraket | |
| Reiko Saito | |||
| P2860 | cites work | Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections | Q26749578 |
| Widespread use of neuraminidase inhibitors in Japan | Q28245805 | ||
| The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza | Q28263414 | ||
| Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers | Q28272841 | ||
| Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance | Q28282405 | ||
| Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants | Q28364114 | ||
| National surveillance of influenza-associated encephalopathy in Japan over six years, before and during the 2009-2010 influenza pandemic | Q28709580 | ||
| Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir | Q30151965 | ||
| Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance | Q30222909 | ||
| In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus. | Q30356466 | ||
| Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor. | Q30362600 | ||
| Favipiravir: a new medication for the Ebola virus disease pandemic. | Q30370190 | ||
| Neuraminidase inhibitors: who, when, where? | Q30371973 | ||
| Substantial Impact of School Closure on the Transmission Dynamics during the Pandemic Flu H1N1-2009 in Oita, Japan. | Q30382523 | ||
| Influenza surveillance system of Japan and acute encephalitis and encephalopathy in the influenza season | Q73772867 | ||
| Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season | Q95561462 | ||
| Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B. | Q40277368 | ||
| Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan. | Q40285211 | ||
| Influenza A virus-associated acute necrotizing encephalopathy in the United States | Q40538481 | ||
| Early administration of oral oseltamivir increases the benefits of influenza treatment | Q40568853 | ||
| Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016. | Q40639592 | ||
| Peramivir is as effective as oral oseltamivir in the treatment of severe seasonal influenza | Q40970018 | ||
| Description of hospitalized cases of influenza A(H1N1)pdm09 infection on the basis of the national hospitalized-case surveillance, 2009-2010, Japan | Q41449549 | ||
| Evaluation of estimated number of influenza patients from national sentinel surveillance using the national database of electronic medical claims | Q41650593 | ||
| Spread of viral infection to family members from influenza patients treated with a neuraminidase inhibitor | Q42221067 | ||
| Long‐Acting Neuraminidase Inhibitor Laninamivir Octanoate versus Oseltamivir for Treatment of Influenza: A Double‐Blind, Randomized, Noninferiority Clinical Trial | Q42862553 | ||
| ECDC expert opinion on efficacy and effectiveness of neuraminidase inhibitors published for public consultation | Q42924849 | ||
| Prognostic factors in influenza-associated encephalopathy. | Q43175713 | ||
| A bad dose of the 'flu | Q43210899 | ||
| Evaluation of two Japanese regulatory actions using medical information databases: a 'Dear Doctor' letter to restrict oseltamivir use in teenagers, and label change caution against co-administration of omeprazole with clopidogrel | Q43828480 | ||
| Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses | Q47886776 | ||
| PCR on cerebrospinal fluid to show influenza-associated acute encephalopathy or encephalitis | Q48393247 | ||
| The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. | Q50656110 | ||
| Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in Japan. | Q51847339 | ||
| Clinical findings in 10 children with H275Y influenza A(H1N1)pdm09 virus infection. | Q53545990 | ||
| Estimated Number of Patients with Influenza A(H1)pdm09, or Other Viral Types, from 2010 to 2014 in Japan | Q30383653 | ||
| Epidemiological characteristics and low case fatality rate of pandemic (H1N1) 2009 in Japan. | Q30384011 | ||
| Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States | Q30400342 | ||
| Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children | Q30404404 | ||
| Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection | Q30408582 | ||
| National survey of pandemic influenza A (H1N1) 2009-associated encephalopathy in Japanese children | Q30418196 | ||
| Epidemiological study of A (H1N1) pdm09 in Iki Island, Nagasaki | Q30418669 | ||
| Genetic characterization of human influenza viruses in the pandemic (2009-2010) and post-pandemic (2010-2011) periods in Japan | Q30418830 | ||
| Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients | Q30424329 | ||
| Effects of vaccination and the new neuraminidase inhibitor, laninamivir, on influenza infection | Q31155532 | ||
| Oral oseltamivir treatment of influenza in children. | Q32064242 | ||
| Encephalitis and encephalopathy associated with an influenza epidemic in Japan | Q33343686 | ||
| T-705 (favipiravir) activity against lethal H5N1 influenza A viruses | Q33639979 | ||
| Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection | Q34023496 | ||
| Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model | Q34040021 | ||
| Favipiravir (T-705), a novel viral RNA polymerase inhibitor | Q34374652 | ||
| Neuraminidase inhibitors for influenza | Q34455162 | ||
| Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients | Q35005030 | ||
| Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants | Q35076812 | ||
| Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials | Q35097867 | ||
| Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection | Q35364093 | ||
| Life-Threatening Abnormal Behavior Incidence in 10-19 Year Old Patients Administered Neuraminidase Inhibitors | Q35680207 | ||
| Effectiveness of Trivalent Inactivated Influenza Vaccine in Children Estimated by a Test-Negative Case-Control Design Study Based on Influenza Rapid Diagnostic Test Results | Q35758531 | ||
| Full Genome Characterization of Human Influenza A/H3N2 Isolates from Asian Countries Reveals a Rare Amantadine Resistance-Conferring Mutation and Novel PB1-F2 Polymorphisms | Q36656494 | ||
| Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza | Q37096782 | ||
| Influenza encephalopathy and related neuropsychiatric syndromes | Q38161554 | ||
| A Review of the Antiviral Susceptibility of Human and Avian Influenza Viruses over the Last Decade | Q38209673 | ||
| The epidemiology and spread of drug resistant human influenza viruses | Q38215346 | ||
| Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. | Q38515079 | ||
| Peramivir: an intravenous neuraminidase inhibitor | Q38543777 | ||
| Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance | Q39239754 | ||
| Influenza Virus Shedding in Laninamivir-Treated Children upon Returning to School | Q40121281 | ||
| Clinical outcome of laninamivir octanoate hydrate for influenza in the 2013-2014 Japanese season | Q40137562 | ||
| Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial | Q40152886 | ||
| Abnormal behavior during influenza in Japan during the last seven seasons: 2006-2007 to 2012-2013. | Q40188256 | ||
| Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013. | Q40207420 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P304 | page(s) | 311-328 | |
| P577 | publication date | 2016-10-10 | |
| P1433 | published in | Current treatment options in infectious diseases | Q26842059 |
| P1476 | title | Japanese Surveillance Systems and Treatment for Influenza | |
| P478 | volume | 8 |
| Q64264514 | A maximum curvature method for estimating epidemic onset of seasonal influenza in Japan |
| Q92647975 | Antibody dynamics in Japanese paediatric patients with influenza A infection treated with neuraminidase inhibitors in a randomised trial |
| Q92134549 | Community spread and late season increased incidence of oseltamivir-resistant influenza A(H1N1) viruses in Norway 2016 |
| Q92437425 | Effectiveness of the quadrivalent inactivated influenza vaccine in Japan during the 2015-2016 season: A test-negative case-control study comparing the results by real time PCR, virus isolation |
| Q61813904 | Incidence of hospitalisation for severe complications of influenza virus infection in Japanese patients between 2012 and 2016: a cross-sectional study using routinely collected administrative data |
| Q64359892 | Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir |
| Q92471636 | New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections |
| Q40110283 | Promising approaches for the treatment and prevention of viral respiratory illnesses |
| Q100681441 | Systematic Approach for Screening of Prodrugs: Evaluation Using Oseltamivir Analogues as Models |
| Q91599874 | The National Influenza Surveillance System of Korea |
| Q59357326 | The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: a prospective, observational study |
| Q53835317 | The safety and efficacy of quadrivalent live attenuated influenza vaccine in Japanese children aged 2-18 years: Results of two phase 3 studies. |
Search more.